| 000 | 01934 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514020618.0 | ||
| 264 | 0 | _c20020307 | |
| 008 | 200203s 0 0 eng d | ||
| 022 | _a1386-6532 | ||
| 024 | 7 |
_a10.1016/s1386-6532(01)00229-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLalezari, Jacob P | |
| 245 | 0 | 0 |
_aHigh dose oral ganciclovir treatment for cytomegalovirus retinitis. _h[electronic resource] |
| 260 |
_bJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology _cFeb 2002 |
||
| 300 |
_a67-77 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xcomplications |
| 650 | 0 | 4 |
_aAcquired Immunodeficiency Syndrome _xcomplications |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCytomegalovirus Retinitis _xcomplications |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGanciclovir _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aVisual Acuity |
| 700 | 1 | _aFriedberg, Dorothy N | |
| 700 | 1 | _aBissett, Jack | |
| 700 | 1 | _aGiordano, Michael F | |
| 700 | 1 | _aHardy, W David | |
| 700 | 1 | _aDrew, W Lawrence | |
| 700 | 1 | _aHubbard, Larry D | |
| 700 | 1 | _aBuhles, William C | |
| 700 | 1 | _aStempien, Mary Jean | |
| 700 | 1 | _aGeorgiou, Panos | |
| 700 | 1 | _aJung, Donald T | |
| 700 | 1 | _aRobinson, Charles A | |
| 773 | 0 |
_tJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology _gvol. 24 _gno. 1-2 _gp. 67-77 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s1386-6532(01)00229-3 _zAvailable from publisher's website |
| 999 |
_c11657478 _d11657478 |
||